Robert Burger
罗伯特·伯格
MD
Professor of Obstetrics and Gynecology, Chief of Gynecologic Oncology妇产科学教授，妇科肿瘤科主任
👥Biography 个人简介
Robert Burger is a leading gynecologic oncologist at the University of Pennsylvania, internationally recognized for his pivotal role in bevacizumab clinical trials in ovarian cancer, helping establish antiangiogenic therapy as a standard treatment option.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Bevacizumab Trials
Led GOG 218, a landmark phase III trial establishing bevacizumab combined with chemotherapy as frontline treatment for advanced ovarian cancer, significantly improving progression-free survival.
Antiangiogenic Therapy
Extensive research defining the role of VEGF inhibition in ovarian cancer management, shaping international treatment guidelines for recurrent and advanced disease.
Representative Works 代表性著作
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
New England Journal of Medicine (2011)
Landmark GOG 218 trial showing bevacizumab plus chemotherapy improves progression-free survival in advanced ovarian cancer.
Phase III Trial of Bevacizumab in Recurrent, Platinum-Resistant Ovarian Cancer
Journal of Clinical Oncology (2014)
Demonstrated bevacizumab efficacy in platinum-resistant recurrent ovarian cancer, influencing standard salvage regimens.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Bradley J. Monk
University of Arizona / HonorHealth
Kathleen N. Moore
Stephenson Cancer Center, University of Oklahoma
Ana Oaknin
Vall d'Hebron University Hospital
Shannon Neville Westin
The University of Texas MD Anderson Cancer Center
关注 罗伯特·伯格 的研究动态
Follow Robert Burger's research updates
留下邮箱，当我们发布与 Robert Burger（University of Pennsylvania）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment